There were no differences in eGFR between the two groups, but there was a reduction in albuminuria with oral semaglutide vs
While the Medicare GLP-1 Bridge Program has expanded access to certain obesity medications for eligible beneficiaries, not everyone with Medicare will qualify
The appropriate response is not avoidance, but disciplined translational design that aligns mechanism, indication, and risk tolerance
Annals of Dermatology, 30 (2), 214217
At the highest doses, retatrutide seems to promise more significant weight loss than existing GLP-1s on the market but as dosage increases, so does the risk of side effects, mostly mild-to-moderate gastrointestinal issues, although one case of pancreatitis occurred in a patient on the 12mg dose during the phase II trial
The clinical differences are more subtle than the price gap suggests